These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22252846)

  • 1. Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
    Toledo Perdomo K; Navarro Cabello MD; Pérez Sáez MJ; Ramos Pérez MJ; Agüera Morales ML; Aljama García P
    J Nephrol; 2012; 25(5):839-42. PubMed ID: 22252846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akinetic mutism induced by tacrolimus.
    Sierra-Hidalgo F; Martínez-Salio A; Moreno-García S; de Pablo-Fernández E; Correas-Callero E; Ruiz-Morales J
    Clin Neuropharmacol; 2009; 32(5):293-4. PubMed ID: 19820432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain syndrome induced by calcineurin inhibitor and resolved by conversion to sirolimus in a child after kidney transplantation: a case report.
    Prates LC; Rigatto SZ; Lutaif AC; Oliveira LC; Pereira LM; Passerotti LC; Belangero VM
    Transplant Proc; 2012 Oct; 44(8):2510-1. PubMed ID: 23026634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
    Wu Q; Marescaux C; Wolff V; Jeung MY; Kessler R; Lauer V; Chen Y
    Eur Neurol; 2010; 64(3):169-77. PubMed ID: 20699617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation.
    Hayes D; Adler B; Turner TL; Mansour HM
    Pediatr Neurol; 2014 Mar; 50(3):272-5. PubMed ID: 24405697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutism and persistent dysarthria due to tacrolimus-based immunosuppression following allogeneic liver transplantation.
    Vearrier D; Simpson SE; Greenberg MI
    Am J Ther; 2011 Nov; 18(6):e274-6. PubMed ID: 20535006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catatonia as a manifestation of tacrolimus-induced neurotoxicity in organ transplant patients: a case series.
    Chopra A; Das P; Rai A; Kuppuswamy PS; Li X; Huston J; Philbrick K; Sola C
    Gen Hosp Psychiatry; 2012; 34(2):209.e9-11. PubMed ID: 21937118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
    Langer RM; Hené R; Vitko S; Christiaans M; Tedesco-Silva H; Ciechanowski K; Cassuto E; Rostaing L; Vilatoba M; Machein U; Ulbricht B; Junge G; Dong G; Pascual J
    Transpl Int; 2012 May; 25(5):592-602. PubMed ID: 22471345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB; Karamperis N; Jørgensen KA
    Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.